This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2001 Oct 6;358(9288):1113-4.

doi: 10.1016/S0140-6736(01)06298-5.

Endothelin-receptor antagonists in pulmonary hypertension

J Dupuis¹

Affiliations

PMID: 11597660
DOI: 10.1016/S0140-6736(01)06298-5

Comment

Endothelin-receptor antagonists in pulmonary hypertension

J Dupuis. Lancet. 2001.

. 2001 Oct 6;358(9288):1113-4.

doi: 10.1016/S0140-6736(01)06298-5.

Author

J Dupuis¹

Affiliation

¹ Montreal Heart Institute and University of Montreal, Montreal, H1T 1C8, Quebec, Canada. dupuisj@icm.umontreal.ca

PMID: 11597660
DOI: 10.1016/S0140-6736(01)06298-5

No abstract available

PubMed Disclaimer

Comment on

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, Rubin LJ. Channick RN, et al. Lancet. 2001 Oct 6;358(9288):1119-23. doi: 10.1016/S0140-6736(01)06250-X. Lancet. 2001. PMID: 11597664 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information